A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Trial Profile

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms LOGICS
  • Sponsors Strongbridge Biopharma
  • Most Recent Events

    • 01 Jul 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 01 Jul 2018 Planned primary completion date changed from 30 May 2018 to 30 May 2019.
    • 02 Apr 2018 According to a Strongbridge Biopharma media release, the first four patients have been dosed and company is expecting topline data in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top